Patients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based on the results of a 27-gene panel, following findings from a meta-analysis.
AstraZeneca's Dave Fredrickson said he expects large advances in blood-based screening and AI-assisted cancer diagnosis and treatment by the year 2040.